Psyched Wellness Initiates the Next Pre-Clinical Trial Study on AME-1

Shares :

0
(0)

Toronto, Ontario–(Newsfile Corp. – April 27, 2021) –  Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that the company and its Clinical Research Organization partner, KGK Science, has commenced the next preclinical trial study with AME-1. 

This new study is a 14-day oral toxicity study of AME-1. It will provide the level of dose(s) that will be selected and administered for a subsequent long term 90-day oral toxicity study. The importance of this study is to determine dose-dependent effects along with determining the highest dose that is safe to use for a longer-term study. This is another key milestone in the further understanding of the effects of Psyched Wellness’ AME-1 extract under a scientific methodology in pursuit of a safe dose for human consumption.

“This represents another milestone event in the scientific study of AME-1. The results of this study will further increase the knowledge and further identify the physical and chemical properties of AME-1” Says Brian Tancowny, scientific advisor for Psyched Wellness.

“The pre-clinical trial we are currently conducting is part of a number of smaller studies that need to happen in a specific order and, when completed, will combine to provide the foundation off of which our future products will be developed,” says Jeff Stevens, CEO of the Company. “As we embark on a new study or complete a study, we add significant value to the Company as we are pioneering a path to market for AME-1 derived health and wellness products.”


Sign up for MORE news updates !


This article is written and published by The Cannabis Stock


Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Click on a star to rate this article !

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.


Shares :